Hyatt Regency Atlanta
Regency VII — Registration and Lunch
Regency VI — Symposium
265 Peachtree Street, NE
Atlanta, GA 30303
12:30 PM EST Registration & Lunch
1:00 PM EST Welcome and Thoughts on MPN Care in the Modern Era
1:10 PM EST MPN Casebook 1: Capturing Elusive PV Presentations: An Under-Recognized Problem?
1:35 PM EST MPN Casebook 2: Targeting Uncontrolled PV: From Recognition to Treatment
2:00 PM EST MPN Casebook 3: Initial Treatment Choices in MF, Risk Models, and Symptom Burden
2:25 PM EST MPN Casebook 4: Allogeneic Transplant in PMF During the JAK Inhibitor Era
2:50 PM EST Take-Home Thoughts and Audience Q&A
3:00 PM EST Adjourn
Philadelphia-chromosome–negative myeloproliferative neoplasms (MPNs) are increasingly recognized as a complex set of disorders that require nuanced approaches to disease recognition, treatment selection, and therapeutic sequencing. This change is fueled by new insights into disease biology for disorders such as polycythemia vera (PV) and myelofibrosis (MF), and the availability of novel, effective therapeutic options such as JAK inhibitors, including for patients who may not present with “classic” disease features at baseline or at any point along the disease continuum.
PeerView will explore these exciting developments in an integrated live/on-demand educational initiative anchored by a Friday Satellite Symposium at the 2017 ASH Annual Meeting. This CME-certified activity will utilize the PeerView Live Casebook format, offering learners a collection of patient stories detailing clinical decision points in key treatment settings in PV and MF, paired with an analysis of the latest evidence on disease management. The cases will also feature point-by-point illustrations of how challenging MPN presentations can be effectively managed with available options despite falling outside of standard characterizations of PV or MF. Learners will also receive case summaries as point of care tools to guide management of MPNs not corresponding to conventional clinical consensus.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, advanced practice oncology nurses, and other healthcare professionals involved in the care of patients with MPN.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.
Release and Expiration Date: December 8, 2017
Time to Complete: 120 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
Ruben A. Mesa, MD, FACP
Director, UT Health San Antonio Cancer Center
Mays Family Foundation Distinguished University Presidential Chair
San Antonio, Texas
Nicolaus Kröger, MD
Professor of Medicine
Department of Stem Cell Transplantation
University Hospital Hamburg-Eppendorf
Francesco Passamonti, MD
Department of Medicine and Surgery
University of Insubria
Robyn M. Scherber, MD
Mayo Clinic in Arizona
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Incyte Corporation.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.